Lung Adjuvant
ALLIANCE A212102 **AT MBMC ONLY** ** As of 2/22/23 participants without a cancer diagnosis will be Temporarily Closed to Enrollment** **White female participants under (<) age 60 without a cancer diagnosis will temporarily be suspended on 12/1/22 3:30 cst**
Blinded Reference Set For Multicancer Early Detection Blood Tests
URCC 19075 **MBMC ONLY** (Temporarily Closed to Enrollment)
Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)
URCC-21038
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
A081801
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
URCC 18007
Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue
ECOG E4512 (NCT02201992) **SUSPENDED** – Must have Consented to ALCHEMIST A151216 Trial
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A151216 (NCT02194738) ALCHEMIST
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)